Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Conditions:   Locally Advanced Undifferentiated Pleomorphic Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Unresectable Undifferentiated Pleomorphic Sarcoma Intervention:   Biological: Sintilimab Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials